Associated Papers
Insights into the role of JAK2-I724T variant in myeloproliferative neoplasms from a unique cohort of New Zealand patients.
Puli'uvea C et al.
Hematology (amsterdam, Netherlands), 2024
A newly identified 45-kDa JAK2 variant with an altered kinase domain structure represents a novel mode of JAK2 kinase inhibitor resistance.
Gorantla SP et al.
Molecular Oncology, 2024
Structural Analysis of Janus Tyrosine Kinase Variants in Hematological Malignancies: Implications for Drug Development and Opportunities for Novel Therapeutic Strategies.
Rodriguez Moncivais OJ et al.
International Journal of Molecular Sciences, 2023
Diagnosis- and Prognosis-Related Gene Alterations in BCR::ABL1-Negative Myeloproliferative Neoplasms.
Morishita S et al.
International Journal of Molecular Sciences, 2023
Mutation profile and immunoscore signature in thymic carcinomas: An exploratory study and review of the literature.
Asselta R et al.
Thoracic Cancer, 2021
Development and validation of a targeted gene sequencing panel for application to disparate cancers.
McCabe MJ et al.
Scientific Reports, 2019
Next-generation sequencing for JAK2 mutation testing: advantages and pitfalls.
Maslah N et al.
Annals of Hematology, 2019
Development of a high resolution melting analysis assay for rapid identification of JAK2 V617F missense mutation and its validation.
Moradabadi A et al.
Experimental Hematology & Oncology, 2019
Validation and Clinical Applications of a Comprehensive Next Generation Sequencing System for Molecular Characterization of Solid Cancer Tissues.
Dehghani M et al.
Frontiers in Molecular Biosciences, 2019
Validation of the Oncomine™ focus panel for next-generation sequencing of clinical tumour samples.
Williams HL et al.
Virchows Archiv : an International Journal of Pathology, 2018
Detection of Exon 12 and 14 Mutations in Janus Kinase 2 Gene Including a Novel Mutant in V617F Negative Polycythemia Vera Patients from Pakistan.
Akram AM et al.
Journal of Cancer, 2018
p.Y317H is a new JAK2 gain-of-function mutation affecting the FERM domain in a myelofibrosis patient with CALR mutation.
Eder-Azanza L et al.
Haematologica, 2017
Apparent 'JAK2-negative' polycythaemia vera due to compound mutations in exon 14.
Tiong IS et al.
British Journal of Haematology, 2017
Mechanistic insights into activation and SOCS3-mediated inhibition of myeloproliferative neoplasm-associated JAK2 mutants from biochemical and structural analyses.
Varghese LN et al.
The Biochemical Journal, 2014
A multiplex snapback primer system for the enrichment and detection of JAK2 V617F and MPL W515L/K mutations in Philadelphia-negative myeloproliferative neoplasms.
Wu Z et al.
Biomed Research International, 2014
Laboratory practice guidelines for detecting and reporting JAK2 and MPL mutations in myeloproliferative neoplasms: a report of the Association for Molecular Pathology.
Gong JZ et al.
The Journal of Molecular Diagnostics : Jmd, 2013
Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations.
Bench AJ et al.
British Journal of Haematology, 2013
Assessment of computational methods for predicting the effects of missense mutations in human cancers.
Gnad F et al.
Bmc Genomics, 2013
Investigation and analysis of single nucleotide polymorphisms in Janus kinase/signal transducer and activator of transcription genes with leukemia.
Zhong Y et al.
Leukemia & Lymphoma, 2012
High resolution melting analysis for JAK2 Exon 14 and Exon 12 mutations: a diagnostic tool for myeloproliferative neoplasms.
Rapado I et al.
The Journal of Molecular Diagnostics : Jmd, 2009
Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera.
Schnittger S et al.
Haematologica, 2009
JAK2 V617F/C618R mutation in a patient with polycythemia vera: a case study and review of the literature.
Yoo JH et al.
Cancer Genetics and Cytogenetics, 2009
Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1.
Tefferi A
Journal of Cellular and Molecular Medicine, 2009
JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies.
Vainchenker W et al.
Seminars in Cell & Developmental Biology, 2008
[The discovery of JAK2 mutation has changed the diagnostic criteria of myeloproliferative neoplasms].
Zhu P
Zhonghua Yi Xue Za Zhi, 2008
Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders.
Walz C et al.
Leukemia, 2008
The saga of JAK2 mutations and translocations in hematologic disorders: pathogenesis, diagnostic and therapeutic prospects, and revised World Health Organization diagnostic criteria for myeloproliferative neoplasms.
Smith CA et al.
Human Pathology, 2008
JAK2 mutations other than V617F: a novel mutation and mini review.
Karow A et al.
Leukemia Research, 2008
Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera.
Pardanani A et al.
Leukemia, 2007
TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.
Pardanani A et al.
Leukemia, 2007
Report on two novel nucleotide exchanges in the JAK2 pseudokinase domain: D620E and E627E.
Schnittger S et al.
Leukemia, 2006
Detection of a new JAK2 D620E mutation in addition to V617F in a patient with polycythemia vera.
Grünebach F et al.
Leukemia, 2006